Nuvectis Pharma, Inc. (NVCT) Analysis
Stock Overview
Volume: 0
Sector: N/A
Industry: N/A
Price Chart
Technical Indicators
Moving Averages
50-Day MA: N/A
200-Day MA: N/A
Relative Strength Index (RSI)
RSI (14): N/A
Neutral
Support & Resistance
Support: $N/A
Resistance: $N/A
52-Week Range
High: $N/A
Low: $N/A
Fundamental Data
Market Cap
N/A
P/E Ratio
N/A
EPS
$N/A
Beta
N/A
Analysis
Note: The analysis provided below is generated for informational purposes only and should not be considered as financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
1. Nuvectis Pharma, Inc. (NVCT) - Up 9.96%
Recent News
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
NEW YORK--(BUSINESS WIRE)---- $NVCT #Cancerstocks--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to dec.
Read Full ArticleHistorical Performance
1 Day
N/A
1 Week
N/A
1 Month
N/A
3 Months
N/A
YTD
N/A
Historical Data
View this stock on other dates:
Recent News
Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation
NEW YORK--(BUSINESS WIRE)---- $NVCT #Cancerstocks--Market News Alerts Reports: Nuvectis Pharma (NASDAQ: NVCT)* announced today that new independent research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University) has demonstrated the superior efficacy of NXP900 when combined with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models. The peer-reviewed study, published in Molecular Cancer Research, demonstrated that the combination therapy led to dec.
Read Full Article